DISEASE CATEGORY: Neurology
INDICATION: Alzheimer’s disease Inhibiting WDR5, a core subunit of the MLL family of histone methyltransferases, or its downstream target SGK1 could treat

Epizyme’s foundational epigenetics hypothesis pays off with approval of first-in-class drug for epithelioid sarcoma

How Argonaut is switching E2F1 from growth to death pathway in cancer cells

Why Third Rock, Fulcrum say the time is ripe for a broader approach to gene control

Novonco ribonucleotide reductase, HMT inhibitors could be safer than predecessors

Epizyme's next first-in-class histone methyltransferase cancer compound